[Form 4] Fennec Pharmaceuticals Inc. Insider Trading Activity

Rhea-AI Filing Summary

Rosty Raykov, a director of Fennec Pharmaceuticals Inc. (FENC), reported a sale of 10,000 common shares on 09/04/2025 at a reported price of $8.92 per share. The Form 4 indicates the sale was made pursuant to a 10b5-1 plan dated August 23, 2024. Following the reported transaction, Mr. Raykov beneficially owns 51,086 shares, held directly. The filing is a routine insider reporting disclosure of this transaction.

Insights

Financial Analyst

TL;DR: Insider sold 10,000 shares under a pre-established 10b5-1 plan; remaining direct ownership is 51,086 shares.

The sale is reported as a routine disposition (Code S) executed under a 10b5-1 plan dated August 23, 2024, which indicates pre-planned timing and generally reduces concerns about opportunistic trading. The reported price is $8.92 per share for 10,000 shares on 09/04/2025. The director retains a meaningful direct stake of 51,086 shares after the sale, and the disclosure complies with Section 16 reporting requirements.

Corporate Governance Expert

TL;DR: Transaction aligns with governance best practices when executed under a documented 10b5-1 plan.

The filing explicitly states the sale was made pursuant to a 10b5-1 written plan, dated August 23, 2024, and the Form 4 is properly signed. Using a 10b5-1 plan provides an affirmative defense under Rule 10b5-1(c) if plan conditions are met. The disclosure shows continued direct ownership of 51,086 shares, maintaining the director's ongoing economic interest in the company.

Insider Trade Summary

Net Seller: 10,000 shares

Net Sell 1 txn

Insider Raykov Rosty

Role Director

Sold 10,000 shs ($89K)

Type	Security	Shares	Price	Value
Sale	Common shares	10,000	$8.92	$89K

Holdings After Transaction: Common shares — 51,086 shares (Direct)

Footnotes (1)

1. F1. Represents shares sold pursuant to a 10b5-1 plan dated August 23, 2024.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 09/04/2025 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Raykov Rosty

(Last) (First) (Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK NC 27709

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares(1)	09/04/2025		S		10,000	D	$8.92	51,086	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold pursuant to a 10b5-1 plan dated August 23, 2024.

	/s/ Rosty Raykov	09/04/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.